DateTitlePlace 
14.05.-16.05.2018   7th General Assembly Meeting       Madrid, Spain
30.11.-02.12.2016   6th General Assembly Meeting       Lisbon, Portugal
 

 

May/June 2018

 

Congratulations to all EMTICS participants and external advisors for a productive and very pleasant final general assembly, held in Madrid in May!

 

EMTICS is finally well into its final phase, which will comprise data analysis and publication of the cross-sectional and longitudinal clinical data. The Methods paper is being submitted in a revised form to European Child and Adolescent Psychiatry and will represent the first clinical research output of the study. As you know, animal model data have already been published with success by the Istituto Superiore di Sanita’ (ISS) team in Rome over the past 2 years. The past 6 months have been dedicated to the definitive categorisation of key clinical events captured in the cohort studies (i.e. exacerbations, onset events) as well as of Group A Streptococcus exposure and collation of clinical and biological data, plus further and final data cleaning. Once again, the Groningen team in UMCG with Andrea Dietrich, Pieter Hoekstra, Maren Person and Thaira Openneer has to be commended for their thorough work in this crucial phase over the past 6 months.

 

An error-free statistical database, containing all clinical and laboratory data, will now be locked for circulation on the 1st of June, and the Codebook has already been circulated across the whole group in November 2017.

 

A call for paper proposals has been sent out, with an initial internal deadline on the 5th of December. Almost 20 paper proposals have been submitted and approved for analysis of the longitudinal data, which add up to those for analysis of the cross-sectional data. Many of these paper proposals have been discussed in Madrid in short oral presentations. Everyone is invited to suggest further paper proposals in the next period, which will be amalgamated and integrated in order to foster collaborations within our large group and avoid overlap.

 

Important preliminary results were also presented by the labs of Alexandroupoli (genetics) and Bari (anti-neuronal antibodies) during the Madrid meeting, and we look forward to their final draft which will certainly provide very important results.

 

The next semester will be characterized by intense data analysis and dense exchange of information and results within the study participants, which hopefully will generate a substantial number of manuscripts to be submitted during the 2018/’19 year. We also anticipate large space to be dedicated to EMTICS data within the 2019 ESSTS yearly conference in Hannover, Germany.

 

We are all looking forward to the data output now, the most exciting part of this long and ambitious collaborative project. Let’s all stay tuned and keep up with our collaboration!

 

 

Here you can find our

Our Grant Agreement and Art. II.30.4 / II.12.2 of our grant agreement lay down the following rules:

  • The following standard disclaimer and acknowledgement is to be written on all publications of EMTICS:

„The project has received funding from the European Union's Seventh Framework Programme for research, technological development and demonstration under grant agreement no 278367.

This paper reflects only the author’s views and the European Union is not liable for any use that may be made of the information contained therein.”

This means for you: Do not forget to include this information in your manuscripts or on your posters or books. It is a contractual duty!

  • Any dissemination activity shall be reported in the plan for the use and dissemination of foreground, including sufficient details/references to enable the Commission to trace the activity.

This means for you: Please keep track of your publications as they need to be reported on in the frame of our periodic reports.

  • With regard to scientific publications relating to foreground published before or after the final report, such details/references and an abstract of the publication must be provided to the Commission at the latest two months following publication. Furthermore, an electronic copy of the published version or the final manuscript accepted for publication shall also be provided to the Commission at the same time for the purpose set out in Article II.12.2 if this does not infringe any rights of third parties.

This means for you: Please send an abstract of your publication to the project office at concentris the moment when it is accepted for publication. concentris will forward it to the relevant services at the EC for you.

  • According to Special Clause 39 of our grant agreement, we are furthermore bound to the following provisions:

In addition to Article II.30.4, beneficiaries shall deposit an electronic copy of the published version or the final manuscript accepted for publication of a scientific publication relating to foreground published before or after the final report in an institutional or subject-based repository at the moment of publication.

Beneficiaries are required to make their best efforts to ensure that this electronic copy becomes freely and electronically available to anyone through this repository:

  • immediately if the scientific publication is published "open access", i.e. if an electronic version is also available free of charge via the publisher, or
  • within 6 months of publication.


In addition to this, the EMTICS Consortium Agreement contains the following provisions:

  • 8.4.1 Publications

Dissemination activities including but not restricted to publications and presentations shall be governed by the procedure of Article II.30.3 of the EC-GA subject to the following provisions.

(1) Prior notice of any planned publication shall be made 45 days before the publication. Any objection to the planned publication shall be made in accordance with the EC-GA in writing to the Coordinator and to any Party concerned within 30 days after receipt of the notice. If no objection is made within the time limit stated above, the publication is permitted.

(2) An objection is justified if

  • the objecting Party's legitimate academic or commercial interests are compromised by the publication; or
  • the protection of the objecting Party's Foreground or Background is adversely affected.

The objection has to include a precise request for necessary modifications.

(3) If an objection has been raised the involved Parties shall discuss how to overcome the justified grounds for the objection on a timely basis (for example by amendment to the planned publication and/or by protecting information before publication) and the objecting Party shall not unreasonably continue the opposition if appropriate actions are performed following the discussion.

This means for you: Please send any manuscript resulting from EMTICS work to the Consortium before publishing it. The Consortium members may object within 30 days.

  • 8.4.2 Publication of another Party’s Foreground or Background

For the avoidance of doubt, a Party shall not publish Foreground or Background of another Party, even if such Foreground or Background is amalgamated with the Party’s Foreground, without the other Party’s prior written approval, which shall not be unreasonably withheld. If the other Party has not raised an objection within 30 (thirty) calendar days after receiving the manuscript, consent to the publication is deemed to be granted.

The following was agreed by the EMTICS Consortium at the Kick-off Meeting in AMSTERDAM:

  • The whole consortium is last author through “the EMTICS consortium”
  • The data base is open to all for publication proposals; the Coordinator will draft and circulate a proposal about publication topic divisions and more detailed publication rules
  • *The group felt that the 45 days until green light of a manuscript for submission is too long in practice. The group agreed on 2 weeks for comments.
  • All centres to send information to the project office (Dr. Sara Stöber) on who is part of the EMTICS consortium from their centre (standard). Of course, people can withdraw from authorship for publications on a case by case basis.

European Multicentre Tics in Children Studies: translating pre-clinical results into therapies



EMTICS aims to identify the genetic and environmental susceptibility factors of tic disorders and will greatly contribute to a better understanding of the underlying mechanisms, especially by elucidating the role of autoimmunity and infections. EMTICS is a project funded by the EU programme FP7 and combines 27 partners from 11 different countries.

Read more

Tic disorders

Tics are characterised by the presence of multiple sudden, rapid, recurrent, and non-rhythmic movements and/or utterances.

About EMTICS

.

Aims of study

EMTICS wants to elucidate the causes of tics in children and to find an effective treatment for the disorder.

About EMTICS

.